# Critical Evaluation: Co-Expression Hypotheses in Alzheimer's Disease
---
## Hypothesis 1: Conserved Synaptic-Mitochondrial Module
### Specific Weaknesses
1. **Correlation ≠ Mechanism**: WGCNA modules identify gene co-expression patterns but provide no information about directionality, causality, or physical interactions. The "compensatory hyperactivity" framing injects interpretation without evidence.
2. **Theoretical Contradiction**: Upregulation of *both* synaptic vesicle genes *and* OXPHOS components conflicts with established AD pathology. Synaptic genes are *downregulated* in AD (Braak stages, proteomics studies), and mitochondrial OXPHOS is *impaired* despite attempted compensation. These are not coherent in a single module.
3. **Cellular Composition Confound**: Bulk tissue RNA-seq from prefrontal cortex, hippocampus, and entorhinal cortex mixes neuronal, glial, and endothelial populations. Changes in relative cell-type abundance (e.g., neuronal loss, astrocyte reactivity) can generate spurious co-expression signals that have nothing to do with the proposed mechanism.
4. **Region Specificity Claims Are Weak**: "Three regions" does not establish conservation. The entorhinal cortex and hippocampus are anatomically contiguous—sharing vascular supply, CSF dynamics, and glia—making correlated signals unsurprising. The prefrontal cortex is more distant. True conservation would require broader sampling.
5. **Non-Specific to AD**: Synaptic disruption and mitochondrial stress occur in Parkinson's disease, frontotemporal dementia, Huntington's disease, and normal aging. If the module is not AD-specific, it cannot be an "AD hallmark."
6. **Missing Mechanistic Bridge**: What molecular mechanism links synaptic and mitochondrial transcriptional changes? Without a proposed regulatory pathway (e.g., a transcription factor, signaling cascade), this is descriptive, not mechanistic.
### Potential Counter-Evidence
- **Meta-analyses of AD transcriptomics** (e.g., Mathys et al., 2019; Allen et al., 2022) show synaptic signaling as *downregulated*, not upregulated, in AD brain.
- Single-nucleus RNA-seq studies reveal distinct cell-type-specific signatures; mitochondrial genes in microglia may drive what appears as "conserved" across regions.
- Mitochondrial proteomics in AD typically show *reduced* complex I/IV activity, not compensatory upregulation.
### Falsification Experiments
| Experiment | What Would Refute It |
|------------|----------------------|
| snRNA-seq decomposition | If module signal comes from different cell types in different regions (e.g., neurons in hippocampus, glia in PFC), the "conserved module" is an artifact |
| Protein-level validation (proteomics, western blot) | If mRNA upregulation does not correspond to protein increase, post-transcriptional regulation dominates |
| AD vs. PD/FTD comparison | If the module appears equally in other neurodegenerative diseases, it is not an AD-specific hallmark |
| Experimental knockdown of hub genes in iPSC neurons | If perturbation disrupts mitochondrial function without affecting synapses (or vice versa), they are not functionally coupled |
### Revised Confidence Score: **0.30**
**Rationale**: The hypothesis has low prior plausibility due to internal contradictions (simultaneous upregulation of synaptic and mitochondrial genes contradicts known AD pathology). Without mechanistic specificity, cell-type resolution, or AD-specificity, this is likely descriptive rather than causal. WGCNA-identified modules frequently fail replication in independent cohorts due to batch effects and sample heterogeneity.
---
## Hypothesis 2: Exosome-Mediated Tau Spreading Module
### Specific Weaknesses